NCT04083183View on ClinicalTrials.gov

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

January 9, 2028

Study Completion Date

January 9, 2028

Conditions
Non-Malignant Neoplasm
Interventions
BIOLOGICAL

Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10

Given IV

DRUG

Fludarabine

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Lapine T-Lymphocyte Immune Globulin

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Hematopoietic Cell Transplantation

Undergo hematopoietic cell transplantation

DRUG

Mycophenolate Mofetil

Given PO or IV

DRUG

Sirolimus

Given PO

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER